EP1742061A4 - Mittel zur vorhersage und beurteilung des wiederauftretens von leberkrebs nach behandlung - Google Patents

Mittel zur vorhersage und beurteilung des wiederauftretens von leberkrebs nach behandlung

Info

Publication number
EP1742061A4
EP1742061A4 EP05736601A EP05736601A EP1742061A4 EP 1742061 A4 EP1742061 A4 EP 1742061A4 EP 05736601 A EP05736601 A EP 05736601A EP 05736601 A EP05736601 A EP 05736601A EP 1742061 A4 EP1742061 A4 EP 1742061A4
Authority
EP
European Patent Office
Prior art keywords
recidival
predicting
evaluating
agent
liver cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05736601A
Other languages
English (en)
French (fr)
Other versions
EP1742061A1 (de
Inventor
Kiyotaka Watanabe
Shin Ohnishi
Hiroyuki Aburatani
Yutaka Midorikawa
Yoshitaka Hippo
Hiroko Iwanari
Susumu Tokita
Hirokazu Satoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perseus Proteomics Inc
Original Assignee
Perseus Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perseus Proteomics Inc filed Critical Perseus Proteomics Inc
Publication of EP1742061A1 publication Critical patent/EP1742061A1/de
Publication of EP1742061A4 publication Critical patent/EP1742061A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP05736601A 2004-04-28 2005-04-28 Mittel zur vorhersage und beurteilung des wiederauftretens von leberkrebs nach behandlung Withdrawn EP1742061A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004134008 2004-04-28
JP2004276704 2004-09-24
PCT/JP2005/008194 WO2005106485A1 (ja) 2004-04-28 2005-04-28 肝癌治療後の再発予測判定薬

Publications (2)

Publication Number Publication Date
EP1742061A1 EP1742061A1 (de) 2007-01-10
EP1742061A4 true EP1742061A4 (de) 2007-11-21

Family

ID=35241795

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05736601A Withdrawn EP1742061A4 (de) 2004-04-28 2005-04-28 Mittel zur vorhersage und beurteilung des wiederauftretens von leberkrebs nach behandlung

Country Status (4)

Country Link
US (1) US7691586B2 (de)
EP (1) EP1742061A4 (de)
JP (1) JP4658926B2 (de)
WO (1) WO2005106485A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2013070468A1 (en) * 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
EP3557260B1 (de) * 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-gerichtetes arzneimittel, das einem patienten verabreicht wird, der auf die gpc3-gerichtete arzneimitteltherapie reagiert
TWI693073B (zh) * 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP3088890B1 (de) 2013-12-24 2020-09-23 Chugai Seiyaku Kabushiki Kaisha Verfahren zur messung von löslichem gpc3-protein
JP6827319B2 (ja) 2014-05-08 2021-02-10 中外製薬株式会社 Ｇｐｃ３標的治療剤療法が有効である患者に投与されるｇｐｃ３標的治療剤
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7096667B2 (ja) 2015-07-01 2022-07-06 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
JP6292564B2 (ja) * 2016-03-10 2018-03-14 シスメックス株式会社 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット
JP6893635B2 (ja) * 2017-03-08 2021-06-23 国立研究開発法人国立がん研究センター 肝細胞がんの早期再発リスクの予測を補助する方法、装置及びコンピュータプログラム
KR102154683B1 (ko) * 2019-11-08 2020-09-11 주식회사 압타머사이언스 글리피칸-3 특이적 변형 압타머 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504222B2 (en) * 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
MXPA04011132A (es) 2002-05-23 2005-08-15 Sunnybrook & Womens College Diagnostico de carcinoma hepatocelular.
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
EP1541680A1 (de) * 2002-09-04 2005-06-15 Chugai Seiyaku Kabushiki Kaisha Antikörper gegen das n-terminale peptid oder das c-terminale peptid von im blut gelöst vorliegendem gpc3

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FUKUZAWA YOSHITAKA ET AL: "Expression of glypican-3 (GPC 3) and its significance as a novel marker of the degree of dedifferentiation in hepatocellular carcinoma (HCC)", HEPATOLOGY, vol. 36, no. 4 Part 2, October 2002 (2002-10-01), & 53RD ANNUAL MEETING ON THE LIVER; BOSTON, MA, USA; NOVEMBER 01-05, 2002, pages 691A, XP008081663, ISSN: 0270-9139 *
NAKATSURA T ET AL: "Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 306, 19 June 2003 (2003-06-19), pages 16 - 25, XP002261242, ISSN: 0006-291X *
See also references of WO2005106485A1 *

Also Published As

Publication number Publication date
EP1742061A1 (de) 2007-01-10
WO2005106485A1 (ja) 2005-11-10
US7691586B2 (en) 2010-04-06
JPWO2005106485A1 (ja) 2008-03-21
JP4658926B2 (ja) 2011-03-23
US20080138827A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
EP1894131A4 (de) Verfahren und systeme zur vorhersage eines krebsergebnisses
EP1571968A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
EP1791477A4 (de) Verbesserte vorrichtung und verfahren für den gefässzugang
PL2278845T3 (pl) Sposoby i urządzenie do dostarczania informacji planowania
MA28936B1 (fr) Canalisation
PL2481756T3 (pl) Kompozycje i sposoby diagnozowania i leczenia nowotworu
DE502005009845D1 (de) Verfahren zum betreiben eines elektromagnetischen durchflussmessers sowie elektromagnetischer durchflussmesser
EP1955156A4 (de) System und verfahren zur entwickler-selbsauswahl auf agent-basis
EP1742061A4 (de) Mittel zur vorhersage und beurteilung des wiederauftretens von leberkrebs nach behandlung
NL1028896A1 (nl) Werkwijze en inrichting voor evaluatie van een beeldscherm.
DE60308433D1 (de) Verfahren für Türanordnung
EP1774043A4 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von krebs
GB0525722D0 (en) Method and system for analyzing multi-phase mixtures
IL189425A0 (en) Device for trapping subsea fresh water resurgences and method for the operation thereof
DE102004021321B8 (de) Verfahren und Einheit zum Ermitteln nutzbarer Dienste
NL1027543A1 (nl) Snel bedienbare sluitinrichting voor biochemische apparatuur.
PT1611890E (pt) Métodos para avaliação e tratamento do cancro
EP2099491A4 (de) Zusammensetzungen und verfahren zur behandlung und diagnostizierung von krebs
EP1824454A4 (de) Gerichtetes eisenchelatorabgabesystem
DE602005023445D1 (de) Malverfahren
TWI346259B (en) Apparatus for developing photoresist and method for operating the same
FI20031433L (fi) Menetelmä valikkojen muodostamiseksi
FI20031083A0 (fi) Menetelmä rikasteiden aikaansaamiseksi
NL1032126A1 (nl) Inrichting en werkwijzen voor immersie lithografie.
ITTO20030678A1 (it) Metodo e apparecchiatura di determinazione quantitativa

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061017

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WATANABE, KIYOTAKA

Inventor name: ABURATANI, HIROYUKI

Inventor name: TOKITA, SUSUMU

Inventor name: HIPPO, YOSHITAKA

Inventor name: SATOH, HIROKAZU,C/O PERSEUS PROTEOMICS INC.

Inventor name: MIDORIKAWA, YUTAKA

Inventor name: OHNISHI, SHIN

Inventor name: IWANARI, HIROKO,C/O PERSEUS PROTEOMICS INC.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20071023

17Q First examination report despatched

Effective date: 20080304

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090421